ÂÜÀòÂÒÂ×

Brian Malik currently serves as a Senior Associate at Catalio Capital Management and holds multiple positions as a Board Observer for companies including NextPoint Therapeutics, Clasp Therapeutics, Pheast Therapeutics, and Ensoma, all since September 2023. Previously, Brian was a Vice President at T. Rowe Price from December 2020 to April 2023 and worked as a Venture Capital Professional at JDRF T1D Fund from June 2019 to December 2020. Brian's experience also includes roles as a Venture Investor and Advisory Committee Member at Sonoma Biotherapeutics and Immunocore, respectively, as well as a Venture Investor at Kriya Therapeutics in 2020. Brian earned a Doctor of Philosophy (PhD) in Immunology from the Geisel School of Medicine at Dartmouth and holds a Bachelor of Science (B.S.) in Cell Biology / Biochemistry from Bucknell University.